5 results ยท Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)diabetic macular edemaActive, not recruitingPhase 32026-09-18NCT06491914
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)Metaplasia, Neovascularization, Pathologic, Pathologic Processes, Pathological Conditions, Signs and Symptoms, age-related macular degeneration, choroidal neovascularization, eye disorder, macular degeneration, optic choroid disorder, retinal degeneration, retinal disorder, uveal disorder, wet macular degenerationRecruitingPhase 2 / Phase 32026-08-06NCT07496567
A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic AtrophyGeographic Atrophy, age-related macular degeneration, eye disorder, macular degeneration, retinal degeneration, retinal disorderActive, not recruitingPhase 22026-05-14NCT06722157
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAKWet Age-related Macular DegenerationActive, not recruitingPhase 32026-04-29NCT06556368
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular DegenerationNeovascular Age-Related Macular DegenerationActive, not recruitingPhase 32025-04-18NCT06223958